Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessio Aghemo

Showing results (61-70 of 318) with videos related to

Pageof 32
Sort By:
Expert Review of Anti-Infective Therapy|October 7, 2009
Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis CAlessio Aghemo, Maria Grazia Rumi, Massimo Colombo
Liver International : Official Journal of the International Association for the Study of the Liver|January 24, 2021
Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirementsLoreta A Kondili, Antonio Craxì, Alessio Aghemo
Journal of Hepatology|January 11, 2012
Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patientsLuca Valenti, Alessio Aghemo, Albert Friedrich Stättermayer
Journal of Hepatology|March 4, 2006
The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremiaMaria Grazia Rumi, Roberta D'Ambrosio, Alessio Aghemo
World Journal of Gastroenterology|March 30, 2013
Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategiesCristina Della Corte, Alessio Aghemo, Massimo Colombo
Annali Dell'Istituto Superiore Di Sanita|September 23, 2021
Challenges on the achievement of World Health Organization goals for HCV elimination in Italy: need for a Regional programmatic approach on screening and linkage to care. CommentaryLoreta A Kondili, Alessio Aghemo, Massimo Andreoni
Nature Reviews. Gastroenterology & Hepatology|July 21, 2010
Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis CAlessio Aghemo, Maria Grazia Rumi, Massimo Colombo
Journal of Viral Hepatitis|March 12, 2008
Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics?Alessio Aghemo, Maria Grazia Rumi, Massimo Colombo
Expert Opinion on Drug Safety|February 25, 2022
Safety of current antiviral drugs for chronic hepatitis BChiara Masetti, Nicola Pugliese, Alessio Aghemo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 25, 2022
No impact of COVID-19 epidemic on decompensation of alcoholic liver disease: Results from a single centre in MilanChiara Masetti, Francesca Colapietro, Antonio Voza, et al.
Pageof 32

Showing results (61-70 of 318) with videos related to

Sort By:
Pageof 32
Expert Review of Anti-Infective Therapy|October 7, 2009
Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis CAlessio Aghemo, Maria Grazia Rumi, Massimo Colombo
Liver International : Official Journal of the International Association for the Study of the Liver|January 24, 2021
Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirementsLoreta A Kondili, Antonio Craxì, Alessio Aghemo
Journal of Hepatology|January 11, 2012
Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patientsLuca Valenti, Alessio Aghemo, Albert Friedrich Stättermayer
Journal of Hepatology|March 4, 2006
The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremiaMaria Grazia Rumi, Roberta D'Ambrosio, Alessio Aghemo
World Journal of Gastroenterology|March 30, 2013
Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategiesCristina Della Corte, Alessio Aghemo, Massimo Colombo
Annali Dell'Istituto Superiore Di Sanita|September 23, 2021
Challenges on the achievement of World Health Organization goals for HCV elimination in Italy: need for a Regional programmatic approach on screening and linkage to care. CommentaryLoreta A Kondili, Alessio Aghemo, Massimo Andreoni
Nature Reviews. Gastroenterology & Hepatology|July 21, 2010
Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis CAlessio Aghemo, Maria Grazia Rumi, Massimo Colombo
Journal of Viral Hepatitis|March 12, 2008
Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics?Alessio Aghemo, Maria Grazia Rumi, Massimo Colombo
Expert Opinion on Drug Safety|February 25, 2022
Safety of current antiviral drugs for chronic hepatitis BChiara Masetti, Nicola Pugliese, Alessio Aghemo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 25, 2022
No impact of COVID-19 epidemic on decompensation of alcoholic liver disease: Results from a single centre in MilanChiara Masetti, Francesca Colapietro, Antonio Voza, et al.
Pageof 32